22 related articles for article (PubMed ID: 38461874)
1. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
2. Inhalable porous particles as dual micro-nano carriers demonstrating efficient lung drug delivery for treatment of tuberculosis.
Campos Pacheco JE; Yalovenko T; Riaz A; Kotov N; Davids C; Persson A; Falkman P; Feiler A; Godaly G; Johnson CM; Ekström M; Pilkington GA; Valetti S
J Control Release; 2024 May; 369():231-250. PubMed ID: 38479444
[TBL] [Abstract][Full Text] [Related]
3. Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment.
Paul PK; Nakpheng T; Paliwal H; Prem Ananth K; Srichana T
Int J Pharm; 2024 Jun; 660():124309. PubMed ID: 38848797
[TBL] [Abstract][Full Text] [Related]
4. Specificity and mechanism of Acinetobacter baumanii nicotinamidase: implications for activation of the front-line tuberculosis drug pyrazinamide.
Fyfe PK; Rao VA; Zemla A; Cameron S; Hunter WN
Angew Chem Int Ed Engl; 2009; 48(48):9176-9. PubMed ID: 19859929
[No Abstract] [Full Text] [Related]
5. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
[TBL] [Abstract][Full Text] [Related]
6. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
7. Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization.
Eedara BB; Fan C; Sinha S; Khadka P; Das SC
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765321
[TBL] [Abstract][Full Text] [Related]
8. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis.
Momin MAM; Thien SJ; Krittaphol W; Das SC
J Pharm Biomed Anal; 2017 Feb; 135():133-139. PubMed ID: 28024261
[TBL] [Abstract][Full Text] [Related]
10. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
Fan C; Eedara BB; Sinha S; Uddin MKM; Doyle C; Banu S; Das SC
Int J Pharm; 2024 Apr; 654():123984. PubMed ID: 38461874
[TBL] [Abstract][Full Text] [Related]
11. Pretomanid for tuberculosis: a systematic review.
Gils T; Lynen L; de Jong BC; Van Deun A; Decroo T
Clin Microbiol Infect; 2022 Jan; 28(1):31-42. PubMed ID: 34400340
[TBL] [Abstract][Full Text] [Related]
12. Leucine as an excipient in spray dried powder for inhalation.
Alhajj N; O'Reilly NJ; Cathcart H
Drug Discov Today; 2021 Oct; 26(10):2384-2396. PubMed ID: 33872799
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
